Owners, management and financials
CVR: 38231170
DKK -38,348,438
Gross profit
Net result: DKK -43,008,287
Novo Holdings A/S (33,33-49,99%), Danmarks Eksport- og Investeringsfond (10-14,99%)
4 more
CVR · view owners
Gonçalo Nuno Nunes da Silva Rebelo de Andrade
Board: Gonçalo Nuno Nunes da Silva Rebelo de Andrade (chair) and 1 member
CVR · view management
Active
Founded 28 November 2016
CVR · view overview
3 employees
CVR · 2026
Director registered: Gonçalo Nuno Nunes da Silva Rebelo de Andrade
CVR · 01/04/2026
View the full event history
Hoba Therapeutics ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2016. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Gonçalo Nuno Nunes da Silva Rebelo de Andrade. The board consists of Gonçalo Nuno Nunes da Silva Rebelo de Andrade (chair) and Gunnar Magnus Severus Modée Persson. The company's owners include Novo Holdings A/S, Danmarks Eksport- og Investeringsfond and EIC Fund. The company has 3 employees (2026). In 2025, the company reported a gross profit of DKK -38,348,438 and a net result of DKK -43,008,287 compared with DKK -27,806,718 the year before. Equity in the 2025 report amounted to DKK 26,061,902.
Selskabets formål er forskning, udvikling og kommercialisering af lægemidler.
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/04/2024 – 31/03/2025 | - | -43 mio. | 46.1 mio. | 26.1 mio. | 8 | |
| 202401/04/2023 – 31/03/2024 | - | -27.8 mio. | 91.5 mio. | 69.1 mio. | 8 | |
| 202301/04/2022 – 31/03/2023 | - | -13.9 mio. | 15.3 mio. | -32.9 mio. | 6 | |
| 202201/04/2021 – 31/03/2022 | 0 | -10.9 mio. | 19.6 mio. | -19 mio. | 3 | |
| 202101/04/2020 – 31/03/2021 | - | -1.9 mio. | 36.5 mio. | 8.2 mio. | 3 | |
| 202001/04/2019 – 31/03/2020 | - | -1.6 mio. | 24.3 mio. | 10.1 mio. | 2 | |
| 201901/04/2018 – 31/03/2019 | - | -1.1 mio. | 15.5 mio. | 11.7 mio. | - | |
| 201801/04/2017 – 31/03/2018 | - | -892 t. | 10.4 mio. | 8.9 mio. | - |
Compared to 1.039 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorThe CVR number of Hoba Therapeutics ApS is 38231170.
The owners of Hoba Therapeutics ApS include Novo Holdings A/S, Danmarks Eksport- og Investeringsfond and EIC Fund.
The management of Hoba Therapeutics ApS consists of Gonçalo Nuno Nunes da Silva Rebelo de Andrade.
The board of Hoba Therapeutics ApS consists of Gonçalo Nuno Nunes da Silva Rebelo de Andrade and Gunnar Magnus Severus Modée Persson, with Gonçalo Nuno Nunes da Silva Rebelo de Andrade as chair.
In 2025, Hoba Therapeutics ApS reported a gross profit of DKK -38,348,438.
Hoba Therapeutics ApS had 3 employees in 2026 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
Contact info changed: new email: [email protected], new website: www.hobatherapeutics.com (June 3, 2026).
As of June 1, 2026, Gonçalo Nuno Nunes da Silva Rebelo de Andrade has joined the board of directors of Hoba Therapeutics ApS.
As of May 31, 2026, Gonçalo Nuno Nunes da Silva Rebelo de Andrade has left the board of directors of Hoba Therapeutics ApS.
As of May 31, 2026, Jean Marcel André Combalbert has left the board of directors of Hoba Therapeutics ApS.
Address changed to Nordre Fasanvej 215, 2000 Frederiksberg (May 13, 2026).
Contact info changed: new email: [email protected], new website: www.hobatherapeutics.com (May 13, 2026).
Contact info changed: new email: [email protected], new website: www.hobatherapeutics.com (April 14, 2026).
As of April 8, 2026, Camilla Petrycer Hansen has left the board of directors of Hoba Therapeutics ApS.
As of April 8, 2026, Kuang He has left the board of directors of Hoba Therapeutics ApS.
As of April 1, 2026, Gonçalo Nuno Nunes da Silva Rebelo de Andrade is registered as adm. dir. of Hoba Therapeutics ApS.
As of March 31, 2026, Jean Marcel André Combalbert has stepped down as adm. dir. of Hoba Therapeutics ApS.
Contact info changed: new email: [email protected], new website: www.hobatherapeutics.com (January 16, 2026).
As of September 19, 2025, Jean Marcel André Combalbert is registered as adm. dir. of Hoba Therapeutics ApS.
As of September 19, 2025, Torsten Meldgaard Madsen has stepped down as adm. dir. of Hoba Therapeutics ApS.
Hoba Therapeutics ApS has published its annual report for 2025. Gross profit came to DKK -38,348,438, and the net result was DKK -43,008,287.
As of September 1, 2025, is registered as an owner of Hoba Therapeutics ApS with an ownership share of 20%.
As of September 1, 2025, is registered as an owner of Hoba Therapeutics ApS with an ownership share of 10%.
As of January 21, 2025, Kuang He has joined the board of directors of Hoba Therapeutics ApS.
As of January 21, 2025, Marie Allen Schroeder has left the board of directors of Hoba Therapeutics ApS.
As of September 10, 2024, Gunnar Magnus Severus Modée Persson has joined the board of directors of Hoba Therapeutics ApS.
As of September 2, 2024, Lene Gerlach has left the board of directors of Hoba Therapeutics ApS.
Hoba Therapeutics ApS has published its annual report for 2024. Gross profit came to DKK -20,860,206, and the net result was DKK -27,806,718.
As of March 1, 2024, Jean Marcel André Combalbert has joined the board of directors of Hoba Therapeutics ApS.
As of March 1, 2024, Amanda Hayward has left the board of directors of Hoba Therapeutics ApS.
As of December 8, 2023, Marie Allen Schroeder has joined the board of directors of Hoba Therapeutics ApS.
As of December 8, 2023, Gonçalo Nuno Nunes da Silva Rebelo de Andrade has joined the board of directors of Hoba Therapeutics ApS.
As of December 8, 2023, Teit Eliot Johansen has left the board of directors of Hoba Therapeutics ApS.
As of December 8, 2023, Morten Døssing has left the board of directors of Hoba Therapeutics ApS.
As of December 8, 2023, Novo Holdings A/S is registered as an owner of Hoba Therapeutics ApS with an ownership share of 33%.
As of December 8, 2023, Danmarks Eksport- og Investeringsfond is registered as an owner of Hoba Therapeutics ApS with an ownership share of 10%.
As of December 8, 2023, is registered as an owner of Hoba Therapeutics ApS with an ownership share of 10%.
As of December 8, 2023, is registered as an owner of Hoba Therapeutics ApS with an ownership share of 5%.
Hoba Therapeutics ApS has published its annual report for 2023. Gross profit came to DKK -9,429,726, and the net result was DKK -13,930,313.
Hoba Therapeutics ApS has published its annual report for 2022. Revenue came to DKK 0, and the net result was DKK -10,898,671.
As of June 28, 2022, EY Godkendt Revisionspartnerselskab has been appointed auditor of Hoba Therapeutics ApS.
As of June 28, 2022, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of Hoba Therapeutics ApS.
As of June 28, 2022, Lene Gerlach has joined the board of directors of Hoba Therapeutics ApS.
As of June 28, 2022, Thor Jespersen has left the board of directors of Hoba Therapeutics ApS.
Hoba Therapeutics ApS has published its annual report for 2021. Gross profit came to DKK 1,392,884, and the net result was DKK -1,944,679.
As of August 24, 2021, Camilla Petrycer Hansen has joined the board of directors of Hoba Therapeutics ApS.
Hoba Therapeutics ApS has published its annual report for 2020. Gross profit came to DKK 838,894, and the net result was DKK -1,582,107.
As of July 1, 2020, Torsten Meldgaard Madsen is registered as adm. dir. of Hoba Therapeutics ApS.
As of July 1, 2020, Kenneth Ahrend Petersen has stepped down as adm. dir. of Hoba Therapeutics ApS.
As of January 31, 2020, Thor Jespersen has joined the board of directors of Hoba Therapeutics ApS.
As of January 31, 2020, Steen Palle Petersen has left the board of directors of Hoba Therapeutics ApS.
Hoba Therapeutics ApS has published its annual report for 2019. Gross profit came to DKK 296,143, and the net result was DKK -1,145,346.
As of November 19, 2018, Steen Palle Petersen has joined the board of directors of Hoba Therapeutics ApS.
As of November 19, 2018, Lene Gerlach has left the board of directors of Hoba Therapeutics ApS.
Hoba Therapeutics ApS has published its annual report for 2018. Gross profit came to DKK 485,419, and the net result was DKK -891,853.
Hoba Therapeutics ApS has published its interim report for the period November 28, 2016 – March 31, 2017.
As of January 1, 2017, Kenneth Ahrend Petersen is registered as adm. dir. of Hoba Therapeutics ApS.
As of January 1, 2017, Morten Døssing has stepped down as director of Hoba Therapeutics ApS.
As of November 29, 2016, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Hoba Therapeutics ApS.
As of November 28, 2016, Teit Eliot Johansen has joined the board of directors of Hoba Therapeutics ApS.
As of November 28, 2016, Lene Gerlach has joined the board of directors of Hoba Therapeutics ApS.
As of November 28, 2016, Morten Døssing has joined the board of directors of Hoba Therapeutics ApS.
As of November 28, 2016, Amanda Hayward has joined the board of directors of Hoba Therapeutics ApS.
As of November 28, 2016, Morten Døssing is registered as director of Hoba Therapeutics ApS.
Hoba Therapeutics ApS was founded on November 28, 2016.
Companies in the same industry and area
CVR 40766383
CVR 42597333
CVR 46613139
CVR 44504332
CVR 43917897
